SCHEMBL24920862

SCHEMBL24920862

COc1nccc(-n2cc(F)cn2)n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.34
MAPK14 Q16539 5/20 0.33
CYP1A2 P05177 4/20 0.33
GRIN1 Q05586 3/20 0.33
GRIN2B Q13224 3/20 0.33
CYP2C19 P33261 3/20 0.33
PRKD3 O94806 2/20 0.33
MAP4K4 O95819 2/20 0.33
PRKCA P17252 2/20 0.33
CSNK1A1 P48729 2/20 0.33
CSNK1D P48730 2/20 0.33
MINK1 Q8N4C8 2/20 0.33
MAP4K5 Q9Y4K4 2/20 0.33
MAPK13 O15264 2/20 0.33
MAPK12 P53778 2/20 0.33
MAPK11 Q15759 2/20 0.33
CYP2C9 P11712 2/20 0.33
KDM4E B2RXH2 1/20 0.33
EGFR P00533 1/20 0.33
RAF1 P04049 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24921233 0.80 CCR1 (0.44) MAPTALDH1A1CCR1CCR5CCR8
SCHEMBL30740344 0.76 TRPV1 (0.39) TDO2EGLN1GRM5GRM4
SCHEMBL31346256 0.76 TDO2 (0.35) TDO2GRM5GRM4
SCHEMBL24921962 0.75 TDO2 (0.34) GRIN1GRIN2BTDO2RXRAEGLN1
SCHEMBL15935022 0.75 BRD4 (0.34) MAPK14CYP1A2GRIN1GRIN2BCYP2C19
SCHEMBL24920900 0.74 PDK2 (0.35) CYP1A2CYP2C19CYP2C9CYP2D6CYP3A4
SCHEMBL24921183 0.74 MAP4K1 (0.41) MAPTKDM4EMEN1ALDH1A1KMT2A
SCHEMBL15923977 0.74 RXRA (0.32) GRIN1GRIN2BRXRA
SCHEMBL19132920 0.73 KDM4E (0.44) MAPTCYP1A2GRIN1GRIN2BCYP2C19
SCHEMBL24920785 0.73 ALKBH1 (0.41) GRIN1GRIN2BTDO2RXRAGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023006097-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER 海创药业股份有限公司 2023-02-02 WO disclosed